

The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this column is a composite with characteristics of several real patients.

Elevated clozapine plasma concentration secondary to a urinary tract infection: proposed mechanisms

Lik Hang N. Lee, BSc; Randall F. White, MD; Alasdair M. Barr, PhD; William G. Honer, MD; Ric M. Procyshyn, PharmD, PhD

A 59-year-old woman was admitted to a tertiary care refractory psychosis unit with a referral diagnosis of schizoaffective disorder. She was maintained on 400 mg of clozapine once daily as part of her pre-existing treatment for auditory hallucinations. The steady state plasma concentrations of clozapine and norclozapine were 2542 and 1465 nmol/L, respectively (metabolic ratio: 1.74). Seven weeks later, the plasma concentrations of clozapine and norclozapine increased to 3272 and 2025 nmol/L, respectively (metabolic ratio: 1.62), despite no changes in medications (including doses), smoking status, or adherence (based on previous clozapine levels). Although no adverse effects were observed in association with the elevated plasma concentrations, the daily dose was reduced to 200 mg as a precautionary measure. Upon investigation, a urinary tract infection (UTI) was diagnosed, for which nitrofurantoin and cotrimoxazole were initiated. After 1 week of antibiotic therapy, clozapine and norclozapine plasma concentrations decreased to 1406 and 639 nmol/L, respectively (metabolic ratio: 2.20).

Similar increases in the plasma concentrations of clozapine and norclozapine have been described in other case reports involving concurrent UTIs.¹⁻⁵ Adverse effects attributed to elevated plasma concentrations of clozapine include somnolence, confusion, disorientation, dizziness, aphasia and extrapyramidal symptoms.¹⁻⁵ Apart from UTIs, this phenomenon has also been reported in association with other infectious processes and with tissue injury,^{1,6-9} sometimes without clozapine-associated adverse effects.¹⁰ The mechanism impli-

cated in increasing plasma concentrations of clozapine and norclozapine is not believed to be related to the exposure to the pathogen or the damage to the tissue, but rather the effects of cytokines released in response to proinflammatory events, such as those mentioned above.¹¹

Several cytokines involved in the acute inflammatory response have been identified as having an inhibitory effect on the expression of certain drug metabolizing enzymes. For instance, a down-regulation of cytochrome P450 (CYP) 1A2 and CYP3A messenger RNA has been reported following the incubation of human hepatocytes with tumour necrosis factor, interleukin (IL)-1 β , and IL-6. Furthermore, the activity of these enzymes were also reduced by the same cytokines.¹² Since clozapine is primarily metabolized by CYP1A2, with contributions from CYP3A4,¹³ reductions in their expression and activity offer an explanation to the noted increase in its plasma concentration. However, this mechanism may not be in operation in our patient since the clozapine/norclozapine metabolic ratios did not increase from baseline to the time of UTI diagnosis. Typically, the ratio would increase to a value greater than 2:1 in response to inhibition of CYP1A2. Interestingly, there was a modest increase in the clozapine/norclozapine metabolic ratio after treatment for the UTI, which is consistent with the inhibitory effect of cotrimoxazole on CYP2C9, an enzyme involved in the demethylation of clozapine to norclozapine.¹⁴

A second mechanism that has been proposed to explain the UTI-associated elevations in the plasma concentrations of clozapine and norclozapine is related to an increase in α 1-acid glycoprotein,¹⁰ an acute-phase protein whose synthesis is upregulated by cytokines such as IL-6.¹⁵ An increase in α 1-acid glycoprotein will increase the binding capacity of both clozapine and norclozapine. The outcome will be an increase in the total (bound and unbound) plasma concentrations of clozapine and norclozapine;

however, the unbound (free and active moiety) concentrations will remain unchanged. Since clinical laboratories report only total (bound and unbound) plasma concentrations, confirmation that the free levels have remained unchanged is not possible. The fact that the patient did not exhibit any clozapine-associated adverse effects supports the supposition that the free concentrations did not increase despite the increase in total concentration. Measuring plasma concentrations of α 1-acid glycoprotein (if available) would have helped to confirm this proposed mechanism.

UTI-associated increases in the plasma concentrations of clozapine and norclozapine are most readily explained by the actions of cytokines on drug metabolism and/or protein binding. Since we could not readily order plasma concentrations of unbound clozapine or α 1-acid glycoprotein, confirmation of the underlying mechanism(s) was not possible. As such, clinicians should monitor for clozapine-associated adverse effects and adjust the dosage accordingly.

Affiliations: From the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia (Lee, Barr); the Department of Psychiatry, University of British Columbia (White, Honer, Procyshyn); the B.C. Psychosis Program, UBC Hospital (White, Honer, Procyshyn); and the British Columbia Mental Health and Addictions Research Institute (Barr, Honer, Procyshyn), Vancouver, B.C., Canada.

Competing interests: R. Procyshyn has received consulting fees from Janssen, Lundbeck, Otsuka, Pfizer, and Sunovion; is on the speaker's bureau for AstraZeneca, Janssen, Lundbeck, Otsuka, and Pfizer; and has received grants from the Canadian Institutes of Health Research (CIHR). A. Barr has received grants from Bristol-Myers Squibb and CIHR. W. Honer has received consulting fees from In Silico, MDH Consulting, Novartis, Eli Lilly, Roche, Otsuka, and Lundbeck; and received grants from CIHR.

Funding: CIHR and B.C. Mental Health and Substance Use Services.

DOI: 10.1503/jpn.150156

References

1. Leung JG, Nelson S, Takala CR, et al. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. *Ann Pharmacother* 2014;48:801-5.
2. Yadav DS, Singh S. Toxic levels of clozapine in a patient with acute urethritis. *Prog Neurol Psychiatry* 2013;17:14-6.
3. Darling P, Huthwaite MA. Infection-associated clozapine toxicity. *Clin Schizophr Relat Psychoses* 2011;5:159-60.
4. Jecel J, Michel TM, Gutknecht L, et al. Toxic clozapine serum levels during acute urinary tract infection: a case report. *Eur J Clin Pharmacol* 2005;60:909-10.
5. Takahashi T, Masuya Y, Ueno K, et al. Clozapine-related negative myoclonus associated with urinary tract infection: a case report. *J Clin Psychopharmacol* 2015;35:205-6.
6. Haack MJ, Bak ML, Beurskens R, et al. Toxic rise of clozapine plasma concentrations in relation to inflammation. *Eur Neuropsychopharmacol* 2003;13:381-5.
7. Raaska K, Raitasuo V, Arstila M, et al. Bacterial pneumonia can increase serum concentration of clozapine. *Eur J Clin Pharmacol* 2002;58:321-2.
8. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. *Prog Neuropsychopharmacol Biol Psychiatry* 2003;27:1059-63.
9. Abou Farha K, van Vliet A, Knegtering H, et al. The value of desmethylclozapine and serum CRP in clozapine toxicity: a case report. *Case Rep Psychiatry* 2012;2012:592784.
10. Espnes KA, Heimdal KO, Spigset O. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. *Ther Drug Monit* 2012;34:489-92.
11. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. *Annu Rev Pharmacol Toxicol* 2006;46:123-49.
12. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome p-450 enzymes in adult human hepatocytes in primary culture. *Mol Pharmacol* 1993;44:707-15.
13. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. *Br J Clin Pharmacol* 1997;44:439-46.
14. Wen X, Wang JS, Backman JT, et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. *Drug Metab Dispos* 2002;30:631-5.
15. Castell JV, Gomez-Lechon MJ, David M, et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. *FEBS Lett* 1988;232:347-50.